14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CLVS ranks #19654 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Clovis Oncology Stock Forecast NASDAQ:CLVS

$1.92 (-8.13%)

Volume: 6M

Closed: Jan 26, 2022

Hollow Logo Score: -5.775

Clovis Oncology Stock Forecast

$1.92 (-8.13%)

Volume: 6M

Closed: Jan 26, 2022

Score Hollow Logo -5.775

Clovis Oncology Company Profile

5500 Flatiron Parkway

Boulder CO 80301



Industry: Biotechnology

Sector: Healthcare

Clovis Oncology


Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. It is developing three product candidates, which include Rociletinib, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor that is under review with the U.S. and E.U. regulatory authorities for the treatment of non-small cell lung cancer; Rucaparib, an oral inhibitor of poly polymerase, which is in advanced clinical development for the treatment of ovarian cancer; and Lucitanib, an oral inhibitor of the tyrosine kinase that is in Phase II development for the treatment of breast cancers. It has license agreements with Advenchen Laboratories LLC, Avila Therapeutics, Inc., and Pfizer Inc.; collaboration and license agreement with Les Laboratoires Servier; a drug discovery collaboration agreement with Array BioPharma Inc.; and collaboration with Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE